Angiogenic Edge of ANGPT2: Genetic Variants Shape Prostate Cancer Prognosis on Androgen Deprivation Therapy
Cancer Genomics - Proteomics · 2025
DOI: 10.21873/cgp.20551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, 2025. Verfasst von Yei-Tsung Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Angiopoietin-2, Polymorphism, Single Nucleotide, Neovascularization, Pathologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Prostate cancer, a leading global malignancy, exhibits variable progression influenced by angiogenesis, the formation of new blood vessels critical for tumor growth and metastasis. We investigated the impact of genetic variants of angiogenesis-related genes on the survival outcomes of patients with prostate cancer receiving androgen deprivation therapy (ADT). MATERIALS AND METHODS: We conducted a genetic association study of 87 single-nucleotide polymorphisms across seven angiogenic genes in 630 patients with prostate cancer undergoing ADT. Survival analysis was used to assess progression-free survival (PFS) and overall survival (OS). Functional analyses, including gene ontology and pathway enrichment, were performed to elucidate the underlying biological mechanisms. RESULTS: ANGPT2 rs2959822 was significantly associated with PFS [hazard ratio (HR)=1.22, p=0.015] and OS (HR=1.22, p=0.021). The minor allele A increased the risk of disease progression and mortality. Functional analyses revealed that rs2959822 influenced ANGPT2 expression. Elevated ANGPT2 expression was correlated with higher Gleason score, advanced tumor stage, and shorter PFS. Gene set enrichment analysis linked ANGPT2 to epithelial-mesenchymal transition (EMT), demonstrating positive correlations with several key EMT genes, along with increased immune cell infiltration, indicating its multifaceted oncogenic roles. CONCLUSION: ANGPT2 rs2959822 influences the survival outcomes of patients with prostate cancer undergoing ADT. In addition to angiogenesis, ANGPT2 plays a critical role in prostate cancer progression by promoting EMT and modulating the tumor immune microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan, R.O.C.
- Department of Pharmacy, China Medical University, Taichung, Taiwan, R.O.C.
- Department of Anatomy, School of Medicine, China Medical University, Taichung, Taiwan, R.O.C.
- Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
- Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
- Department of Urology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, R.O.C.
Zitieren
APA
Chen, Y. T., Chen, P. Y., Chang, C. F., Huang, C. Y., Yu, C. C., Lin, V. C., Chang, H. H., Lu, T. L., Huang, S. P., & Bao, B. Y. (2025). Angiogenic Edge of ANGPT2: Genetic Variants Shape Prostate Cancer Prognosis on Androgen Deprivation Therapy. Cancer Genomics - Proteomics. https://doi.org/10.21873/cgp.20551
Vancouver
Chen YT, Chen PY, Chang CF, Huang CY, Yu CC, Lin VC, et al. Angiogenic Edge of ANGPT2: Genetic Variants Shape Prostate Cancer Prognosis on Androgen Deprivation Therapy. Cancer Genomics - Proteomics. 2025. doi:10.21873/cgp.20551
BibTeX
@article{Chen2025,
author = {Chen, Yei-Tsung and Chen, Pin-Yi and Chang, Chi-Fen and Huang, Chao-Yuan and Yu, Chia-Cheng and Lin, Victor C and Chang, Hao-Han and Lu, Te-Ling and Huang, Shu-Pin and Bao, Bo-Ying},
title = {Angiogenic Edge of ANGPT2: Genetic Variants Shape Prostate Cancer Prognosis on Androgen Deprivation Therapy},
journal = {Cancer Genomics - Proteomics},
year = {2025},
doi = {10.21873/cgp.20551}
}
EUVIMED